Aphria cutting US marijuana exposure amid delisting review

Just Released! Get realistic market forecasts, state-by-state insights and benchmarks with the new 2024 MJBiz Factbook member program, now with quarterly updates. Make informed decisions.

Aphria is scrambling to shed direct involvement in American medical cannabis businesses as it undergoes a delisting review by its stock exchange operator.

The Leamington, Ontario-based company has been in the hot seat since the TMX Group – parent of the Toronto Stock Exchange and the TSX Venture Exchange – said companies with direct business ties in American marijuana companies could be delisted from its platforms.

Now Aphria – traded on the Toronto Stock Exchange under the symbol APH – is moving to “purify” its balance sheet, The Canadian Press reported.

That involves shifting its direct stakes in American MMJ companies to its American affiliate, Liberty Health Sciences.

Aphria has direct investments in Arizona’s Copperstate Farms and Colorado-based MassRoots.

CEO Vic Neufeld said the company is in discussions with TMX Group, and the review will be completed before the new year.

If that doesn’t satisfy TMX Group, Neufeld said the company’s last step would be to spin off Aphria’s U.S. interests and list them on the Canadian Securities Exchange.

To sign up for our weekly Canada marijuana business newsletter, click here.